Plain-English translation of NCT06212323 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Smoldering myeloma is an early form of blood cancer that isn't yet causing symptoms or organ damage, but some patients have features that put them at higher risk of developing active myeloma. This study is observing patients with high-risk smoldering myeloma over time to better understand how the disease develops and progresses when they receive careful, regular monitoring with standard care and special MRI scans that can detect changes in bone marrow.
Doctors don't yet have a clear picture of how high-risk smoldering myeloma evolves in patients today, especially with modern monitoring tools. This study aims to fill that gap so doctors can better predict which patients will develop active myeloma and need treatment sooner.
You likely qualify if…
You likely don't qualify if…
You would visit your doctor regularly for standard myeloma monitoring, including blood tests to check your myeloma markers. The main addition to routine care is that you'll receive periodic whole-body MRI scans (a type of advanced imaging) to track changes in your bone marrow over time. The study will follow you for as long as needed to understand how your disease progresses, and researchers will use the information from your medical records and imaging to build a better picture of high-risk smoldering myeloma.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States
Sponsor
University of Utah
Enrollment target
~100 participants
Started
January 2024
Primary completion
March 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sharmilee Nuli
Huntsman Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.